CA3098277A1 - Use of canakinumab - Google Patents

Use of canakinumab Download PDF

Info

Publication number
CA3098277A1
CA3098277A1 CA3098277A CA3098277A CA3098277A1 CA 3098277 A1 CA3098277 A1 CA 3098277A1 CA 3098277 A CA3098277 A CA 3098277A CA 3098277 A CA3098277 A CA 3098277A CA 3098277 A1 CA3098277 A1 CA 3098277A1
Authority
CA
Canada
Prior art keywords
canakinumab
patient
hscrp
administration
lbeta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3098277A
Other languages
English (en)
French (fr)
Inventor
Mattias SCHIEKER
Linda Mindeholm
Jens PRAESTGAARD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA3098277A1 publication Critical patent/CA3098277A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3098277A 2018-05-09 2018-08-24 Use of canakinumab Abandoned CA3098277A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862669071P 2018-05-09 2018-05-09
US62/669,071 2018-05-09
PCT/IB2018/056455 WO2019215484A1 (en) 2018-05-09 2018-08-24 Use of canakinumab

Publications (1)

Publication Number Publication Date
CA3098277A1 true CA3098277A1 (en) 2019-11-14

Family

ID=63638190

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3098277A Abandoned CA3098277A1 (en) 2018-05-09 2018-08-24 Use of canakinumab

Country Status (12)

Country Link
US (1) US20210371511A1 (https=)
EP (1) EP3790576A1 (https=)
JP (2) JP2021523894A (https=)
KR (1) KR20210008847A (https=)
CN (2) CN119746057A (https=)
AU (1) AU2018422406A1 (https=)
BR (1) BR112020022576A2 (https=)
CA (1) CA3098277A1 (https=)
CL (1) CL2020002881A1 (https=)
MX (1) MX2020011909A (https=)
TW (1) TW201946652A (https=)
WO (1) WO2019215484A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112402359A (zh) * 2020-11-04 2021-02-26 深圳前海鹰岗生物科技有限公司 一种抑制细胞炎症因子治疗痛风急性发作的聚合物微针及制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
TR201802449T4 (tr) * 2005-10-26 2018-03-21 Novartis Ag Ailesel akdeniz hummasının anti ıl-1beta antikorları ile tedavisi.
MX362591B (es) * 2010-11-05 2019-01-25 Novartis Ag Uso de antagonistas de il-17.
BR112014007253A2 (pt) 2011-09-30 2017-03-28 Novartis Ag uso de anticorpos que se ligam a il-1beta
WO2015084883A2 (en) * 2013-12-02 2015-06-11 Abbvie, Inc. Compositions and methods for treating osteoarthritis
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
UY37758A (es) * 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
JP2020524694A (ja) * 2017-06-22 2020-08-20 ノバルティス アーゲー がんの処置における使用のためのＩＬ−１β結合性抗体
CN107723310B (zh) * 2017-10-19 2024-01-09 北京睿诚海汇健康科技有限公司 植物作为宿主在表达卡那抗体中的应用

Also Published As

Publication number Publication date
CN119746057A (zh) 2025-04-04
CN112584857A (zh) 2021-03-30
JP2021523894A (ja) 2021-09-09
BR112020022576A2 (pt) 2021-02-09
EP3790576A1 (en) 2021-03-17
WO2019215484A1 (en) 2019-11-14
CL2020002881A1 (es) 2021-05-14
KR20210008847A (ko) 2021-01-25
US20210371511A1 (en) 2021-12-02
TW201946652A (zh) 2019-12-16
AU2018422406A1 (en) 2020-11-12
MX2020011909A (es) 2021-01-29
JP2023071904A (ja) 2023-05-23
JP7713983B2 (ja) 2025-07-28

Similar Documents

Publication Publication Date Title
JP6515168B2 (ja) Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法
JP2021503476A (ja) Ｉｌ−１７アンタゴニストを用いて化膿性汗腺炎を治療すること
RU2697383C2 (ru) Применение антагонистов il-17 для торможения прогрессирования структурных повреждений у пациентов с псориатическим артритом
US20230331834A1 (en) Method of treating tendinopathy using interleukin-17 (il-17)
AU2014360704A1 (en) Compositions and methods for treating osteoarthritis
JP7713983B2 (ja) カナキヌマブの使用
JP2025516723A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を選択的に治療する方法
JP2025537802A (ja) トランスサイレチン媒介アミロイドーシスを治療又は予防する方法
WO2025083621A1 (en) Treatment of hidradenitis suppurativa using anti-baff-r antibodies

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20240226